Shareholding disclosure

NeoMed Innovation IV

Declared position

3.18%

Threshold

Crossed upwards

Timeline

Published

17.01.2008

Transaction

01.12.2007

Transfer date

01.12.2007

Voting rights breakdown

Voting rights acquired3.18%

Voting rights sold0%

Below threshold0%

Notice details

CategoryGroup of shareholders

ExchangeXSWX

Notification ID

T5585D5345

Beneficial owner

NeoMed Innovation IV

Declared address

NeoMed Innovation IV, St. Helier

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

NeoMed Innovation IV

Santhera Pharmaceuticals Holding AG17.01.2008T5585D5345

Disclosure summary

NeoMed Innovation IV disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 17.01.2008, at 3.18% of voting rights. Notice category: Group of shareholders.

Disclosed position

3.18%

Voting rights acquired

Voting rights acquired3.18%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

NeoMed Innovation IV disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 17.01.2008.

Publication date17.01.2008

Transaction date01.12.2007

Transfer date01.12.2007

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerNeoMed Innovation IV

Declared addressNeoMed Innovation IV, St. Helier

CategoryGroup of shareholders

Voting rights acquired3.18%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDT5585D5345

Source: SIX Exchange Regulation · Publication date: 17.01.2008

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open